Nasdaq · Healthcare
TG THERAPEUTICS, INC. (TGTX)
As-reported financials and recent SEC filings for TG THERAPEUTICS, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$616.3M
Net income
$447.2M
Net margin
72.6%
Diluted EPS
$2.77
ROE
69.0%
P/E (TTM)
19.5×
Market cap
$8.55B
Debt / equity
0.4×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2023 | FY2023 |
|---|---|---|---|---|---|
| Revenue | $616.3M | $329.0M | $233.7M | $2.8M | $6.7M |
| Gross profit | $515.6M | $290.5M | — | $2.5M | $5.9M |
| Operating income | $123.3M | $41.9M | $20.6M | $-218.3M | $-344.8M |
| Net income | $447.2M | $23.4M | $12.7M | $-223.8M | $-348.1M |
| Diluted EPS | $2.77 | $0.15 | $0.09 | $-1.65 | $-2.63 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →8-K2026-06-12
View on EDGAR →8-K2026-06-03
View on EDGAR →8-K2026-05-27
View on EDGAR →Go deeper on TGTX
Search TG THERAPEUTICS, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.